Soricimed Gets Positive Trial Results

Sackville, N.B.-based Soricimed Biopharma Inc. has received positive initial readings from the Phase 1 trials of its flagship compound SOR-C13, including indications that it can stabilize some cancer tumours.
Sor-C13 is a peptide, or a naturally occurring biological molecule, that clings to the calcium in a cancer cell and deprives it of oxygen, thereby killing the tumour. Soricimed hopes to